Search Within

Andrew D Zelenetz

  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (29)
  2. Journal Article (12)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. CTCR Scholars (44)
  2. Center for Hematologic Malignancies (44)
  3. Department of Medicine (44)
  4. Hematologic Malignancies, Division of (44)
  5. Lymphoma (44)
  6. MSK Grad Students (44)

More Groups

People
  1. Ariela Noy (37)
  2. Matthew Matasar (36)
  3. Alison Moskowitz (34)
  4. Anita Kumar (34)
  5. Steven Horwitz (34)
  6. Paul Hamlin (33)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (3)
  4. 2022 (3)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Blood (23)
  2. Journal of Clinical Oncology (4)
  3. Blood Advances (3)
  4. Blood Cancer Journal (3)
  5. Hematological Oncology (3)
  6. Leukemia and Lymphoma (3)

More Publications

Publishers
  1. American Society of Hematology (26)
  2. American Society of Clinical Oncology (4)
  3. Elsevier Inc. (3)
  4. Nature Publishing Group (3)
  5. Taylor & Francis Group (3)
  6. Wiley Blackwell (3)

More Publishers

Results (44)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma
    Research Letter

    Deschenes-Simard, X.; Pennisi, M.; Perales, M. A.; Shah, G. L.; Zelenetz, A. D.; Yahalom, J.; Imber, B. S.; Santomasso, B. D.; Dahi, P. B.
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience
    Journal Article

    Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save